EarlyDiagnostics’ MethylScan™ Platform Validated in PNAS Study
EarlyDiagnostics (EarlyDx) has announced that its MethylScan™ platform has been validated in a study published in PNAS, demonstrating the ability to detect multiple diseases from a single blood sample.
LOS ANGELES–(BUSINESS WIRE)– #Biotech–EarlyDiagnostics (EarlyDx) announced PNAS validation of its MethylScan™ platform for multi-disease detection from a single blood sample.